Edgewise Therapeutics (EWTX) Operating Leases (2022 - 2026)

Edgewise Therapeutics has disclosed Operating Leases across 5 years of filings, most recently posting $2.8 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $2.8 million, down 21.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (down 21.96% YoY), and the FY2025 annual result was $3.0 million, down 20.45% from the prior year.
• Operating Leases came in at $2.8 million for Q1 2026 at Edgewise Therapeutics, down from $3.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $4.8 million in Q1 2023 to a low of $1.6 million in Q2 2022.
• The 5-year median for Operating Leases is $3.6 million (2025), against an average of $3.5 million.
• Across the five-year window, Operating Leases jumped 191.56% in 2023 and declined 25.03% in 2024, its largest moves.
• Edgewise Therapeutics' Operating Leases stood at $3.8 million in 2022, then rose by 16.68% to $4.4 million in 2023, then fell by 15.63% to $3.7 million in 2024, then slipped by 20.45% to $3.0 million in 2025, then slipped by 6.72% to $2.8 million in 2026.
• The last three Operating Leases figures came in at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.